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ABSTRACT
The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an
increasing clinical importance, thanks to their speciﬁcity, efﬁcacy and relative easiness of use. However, in
the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can beneﬁt from
therapeutic mAb targeting speciﬁc B-cell lineage antigens. To overcome this limitation, we generated a
new mAb speciﬁc for BARF1, an EBV-encoded protein with transforming and immune-modulating
properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC),
and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all
EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb
was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor
cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and
was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo,
biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells conﬁrmed its
high speciﬁcity for the target. More importantly, the mAb disclosed a relevant antitumor potential in
preclinical models of NPC and lymphoma, as evaluated in terms of both reduction of tumor masses and
long-term survival. Taken together, these data not only conﬁrm BARF1 as a promising target for
immunotherapeutic interventions, but also pave the way for a successful translation of this new mAb to
the clinical use.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity;
CFA, complete Freud adjuvant; CTLs, cytotoxic T lymphocytes; EBV, Epstein-Barr virus; ELISA, enzyme-linked immu-
nosorbent assay; hCSF-1, human colony-stimulating factor; IFA, incomplete Freud adjuvant; IFN-a, interferon-a; LV-
LUX, luciferase-encoding lentiviral vector; mAbs, monoclonal antibodies; NK, natural killer; NPC, nasopharyngeal
carcinoma; PEG, polyethyleneglycol; PTLD, post-transplant lymphoproliferative disease; PVDF, polyvinylidene ﬂuo-
ride; RAG, recombination-activating gene; SCID, severe combined immunodeﬁciency
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Introduction
The Epstein-Barr virus (EBV) is a g-herpesvirus associated
with the development of both lymphoid and epithelial malig-
nancies, each characterized by a distinct pattern of viral protein
expression.1 Since viral proteins are expressed almost exclu-
sively in malignant cells, they represent an ideal target for
immunotherapeutic strategies, as demonstrated by the success
of EBV-speciﬁc adoptive T-cell therapy, especially against post-
transplant lymphoproliferative disease (PTLD) in which the
full array of latent EBV proteins is expressed.2 However, albeit
highly heterogeneous, the infused cytotoxic T lymphocytes
(CTLs) are able to target only a few subdominant EBV anti-
gens, such as LMP-1 and LMP-2, thus accounting for the less
satisfactory results obtained against tumors characterized by a
restricted pattern of latent protein expression.2
One of these “neglected” proteins is represented by BARF1,
which recently proved to be a very attractive target for improv-
ing adoptive immunotherapy of nasopharyngeal carcinoma
(NPC).3,4 Unlike classic EBV tumor-associated latency pro-
teins, BARF1 is mainly considered an early lytic protein in a
normal B-cell background, whereas it is consistently expressed
during latency in EBV-related NPC and gastric carcinoma
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(GC).5-7 Whether BARF1 is also expressed in EBV latently
infected lymphoma cells, remains to be elucidated.
BARF1 is a 221 amino acid (aa) transmembrane protein
expressed at the surface of EBV-infected cells, although the extra-
cellular domain can be cleaved after the ﬁrst 20 aa and shed, thus
exerting its pleiotropic functions both in cis and in trans. Indeed,
BARF1 was shown to immortalize simian and human epithelial
cells,8,9 and human B lymphocytes.10 Importantly, mouse ﬁbro-
blasts immortalized upon BARF1 transfection-induced tumors
when injected in newborn rodents.11 Ectopic expression of
BARF1 or treatment of cells with its secreted form were shown to
promote the growth of different cell types, including mouse ﬁbro-
blasts, human B cells, primary monkey and human epithelial
cells.12 Interestingly, this autocrine/paracrine cell growth promo-
tion can be blocked by anti-BARF1 antibodies.13,14
Immortalizing and transforming properties of BARF1 are
dependent on the activation of various intracellular signaling
pathways including c-myc activation,10 induction of cyclin-D
expression,15 upregulation of the anti-apoptotic molecule
Bcl¡2,16 and SMAD4 suppression through NF-kB-mediated
miR-146a upregulation.17 In addition, due to a limited homol-
ogy with the human colony-stimulating factor 1 (hCSF1) recep-
tor, BARF1 may act as an allosteric decoy receptor for hCSF1,18
thereby interfering with human monocyte and macrophage dif-
ferentiation and activity via down-modulation of surface marker
expression, reduction of cell viability19 and IFNa release.20 By
manipulating monocyte and macrophage physiology, BARF1
may therefore exert an immune-modulating role thus contribut-
ing to render the tumor invisible to the immune system.
On these grounds, BARF1 can be regarded as an ideal candi-
date for a monoclonal antibody (mAb) therapy, both in its
membrane-associated and shed forms. We therefore aimed at
developing a novel BARF1-speciﬁc mAb for passive immuno-
therapy of EBV-related malignancies. In this regard, BARF1-
speciﬁc polyclonal and monoclonal antibodies described thus
far have not been tested for immunotherapeutic approaches.
Here, we describe the successful generation of a BARF1-speciﬁc
monoclonal antibody and its in vitro and in vivo functional
characterization. The mAb proved to be effective in comple-
ment-dependent cytotoxicity (CDC) and antibody-dependent
cell-mediated cytotoxicity (ADCC) assays against a panel of
BARF1-positive tumor cells. Moreover, biodistribution analysis
exploiting in vivo ﬂuorescence imaging demonstrated its spe-
ciﬁc targeting to EBV-related tumor masses. In immunother-
apy experiments involving BARF1-positive NPC and
lymphoma preclinical models, the mAb restrained tumor
growth and improved long-term survival of treated animals.
Taken together, these data corroborate the role of BARF1 as
a novel EBV-speciﬁc tumor antigen suitable for immunothera-
peutic approaches, and support the concept that anti-BARF1
mAb can be regarded as promising new tools for the treatment
of most EBV-related malignancies.
Results
Immunization and monoclonal antibody production
Conventional BALB/c mice were immunized with KLH-conju-
gated peptides (BARF1201–221, BARF1104–120 and BARF128–38;
Fig. 1A) according to a routine schedule, and sera were col-
lected and analyzed by ELISA test. All the peptides used for
immunization induced strong antibody production that
resulted in elevated absorbance values even at very high sera
dilutions (data not shown), thus demonstrating the immuno-
genicity of the KLH-conjugated peptides. Since BARF1 is
expressed on the surface of EBV-infected cells,21 we decided to
use GRANTA-519 cell line, a human mantle lymphoma cell
line expressing EBV and BARF1 mRNA,3 to screen mouse sera
by ﬂow cytometry. After the ﬁrst round of three immuniza-
tions, GRANTA-519 resulted negative, thus requiring addi-
tional immunizations of mice before a detectable signal was
evident. Interestingly, peptide-speciﬁc immunoglobulin titres,
as assessed by ELISA, remained almost at the same maximal
levels, indicating that antibody titres did not increase but
improved in terms of intrinsic afﬁnity and ability to recognize
naturally folded epitopes that are physiologically presented on
the cell surface. After hybridoma generation from the best
reactive mouse, the same ELISA and ﬂow cytometry-based
screenings were also adopted to analyze the derived clones,
ultimately leading to the selection of a single clone (3D4, an
IgG2a-secreting hybridoma derived from a mouse immunized
with peptide BARF128–38) that was chosen for subsequent
analyses.
As a ﬁrst proof of BARF1 target recognition, the 3D4 anti-
body was used in a Dot Blot assay. All the peptides used for
immunization, and two 4-aa overlapping peptides derived from
peptide BARF128–38, were spotted on PVDF to identify the epi-
tope recognized by anti-BARF1 antibody. Dot blot analysis
revealed that the 3D4 mAb did not recognize unrelated pepti-
des (BARF1201–221 and BARF1104–120), while the BARF128–38
peptide was positively stained. Of the two additional peptides
derived from peptide BARF128–38, only peptide BARF128–35
was recognized by the 3D4 mAb, thus indicating that the recog-
nized epitope resides within its sequence (Fig. 1A). BLAST
analysis revealed that the peptide sequence is speciﬁc for the
BARF1 protein and for the human colony-stimulating factor 1
receptor (hCSF-1 receptor), which is known to share homology
with BARF1 protein.22
The 3D4 mAb speciﬁcally identiﬁes BARF1 on tumor cell
lines of different histotypes
The anti-BARF1 3D4 mAb stained EBVCBARF1C tumor cell
lines belonging to different histotypes, whereas EBV-negative
and BARF1-negative cells were not stained (Fig. 1B). Notably,
the EBVC Raji cell line was not recognized by the 3D4 mAb,
consistently with its negativity for BARF1 expression due to a
deletion in the corresponding gene within the EBV genome,23
thus further supporting the speciﬁcity of the mAb. The differ-
ences in the mean ﬂuorescence intensity observed among the
positive cells are likely to be ascribed to the differential expres-
sion of BARF1. Indeed, few information is available about
BARF1 expression levels on the cell surface, so that we may
expect a differential protein expression on different cell lines,
or on the same cell line but at different culture stages (in fresh
medium rather than in an exhausted, acidiﬁed medium).
Moreover, cleavage of the extracellular BARF1 domain has
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been reported, even though the cleavage rate is still to be
elucidated.24
To further conﬁrm the speciﬁcity of the antibody for its tar-
get, we ectopically expressed BARF1 in the EBV-negative
MKN-45 GC cell line. As shown in Fig. 1C, the 3D4 mAb
clearly labeled BARF1-transduced MKN-45 cell line, whereas
parental cells showed only background staining, thus demon-
strating the ﬁne speciﬁcity of the mAb.
The 3D4 mAb mediates both CDC and ADCC in vitro
Complement-dependent cytolysis (CDC) was assessed in a stan-
dard chromium release assay, using both EBV-positive and -neg-
ative cell lines as target cells. As shown in Fig. 2A, EBV-positive
cell lines (GRANTA-519, C-666, BL-41 B95.8 and SNU-719)
were speciﬁcally lysed when exposed to both 3D4 mAb and com-
plement; in the same experimental conditions, the EBV-negative
BL-41 cell line showed only a background level of lysis.
ADCC was performed using Calcein AM on the same
panel of EBV-positive and -negative cells already used in
CDC, with PBMC from healthy donors serving as effector
cells. As shown in Fig. 2B, the 3D4 mAb was able to speciﬁ-
cally mediate ADCC of BARF1C target cells. The highest level
of lysis of BARF1-positive target cells was obtained with
20 mg/mL of the 3D4 mAb at an effector:target ratio of 300.
As evaluated by ﬂow cytometry, the percentage of
CD16CCD56C NK cells in PBMC was in the range of 12–15%
of the total population (data not shown).
The 3D4 mAb speciﬁcally targets BARF1-positive tumors
in vivo
Biodistribution analysis and in vivo targeting capacity of the
mAb were assessed by tracking the ﬂuorescence signal of
Alexa-680-conjugated anti-BARF1 antibody, following injec-
tion in mice grafted with EBV-positive (C-666) or -negative
Figure 1. BARF1 mAb generation and characterization. (A) Left: BARF1 sequence (NCBI Reference Sequence: YP_401719.1) and derived peptides. Right: dot Blot analysis.
Peptides BARF1201–221, BARF1104–120 and BARF128–38 are highlighted in the amino acidic sequence of the whole protein. A positive staining was detected only on peptide
BARF128–38 and the derived BARF128–35, thus identifying the minimal epitope of the selected antigen. (B) Flow cytometry analysis of BARF1 expression by GRANTA-519, C-
666, BL-41 B95.8, SNU-719, BJAB, RAJI and BL-41 cell lines. (C) Flow cytometry analysis of BARF1 expression by MKN-45 cells before and after transduction with a BARF1-
coding retrovirus.
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(MKN-45) cell lines at two distinct sites. The analysis was
performed daily for 1 week, and the values of ﬂuorescence
intensity were recorded for the two tumor masses. As previ-
ously reported,25 a whole intact mouse mAb requires at
least 3 d to accumulate differentially at the site of antigen-
expressing tumor; indeed, by day 3, the 3D4 mAb showed a
markedly higher accumulation at the site of BARF1C C-666
tumor mass, as compared with the EBV-negative counter-
part (Fig. 3A). As an additional proof of speciﬁcity, the
same biodistribution analysis was performed in mice
injected at two distinct sites with untransduced or BARF1-
transduced MKN-45 cells. Again, a strong and highly
speciﬁc signal could be progressively detected only from the
BARF1C MKN-45 cancer mass (Fig. 3B), thus indicating
that the 3D4 mAb is speciﬁc for the BARF1 protein and
capable of recognizing the viral antigen also in vivo.
Administration of 3D4 mAb to tumor-bearing mice
restrains primitive cancer growth and reduces metastatic
spreading
Tumor cell lines of different histotypes were injected in SCID
mice either s.c. or i.v. to evaluate the therapeutic activity of
anti-BARF1 antibody in tumor mouse models. In the C-666
Figure 2. BARF1 mAb in vitro functional activity. (A) CDC. Speciﬁc lysis of EBV-positive (GRANTA-519, C-666, BL-41 B95.8 and SNU-719) and -negative (BL-41) cell
lines after exposure to the 3D4 anti-BARF1 mAb and Complement. The isotype control and Complement alone were used as negative controls. (B) ADCC. Spe-
ciﬁc lysis of EBV-positive and EBV-negative cell lines after exposure to the 3D4 anti-BARF1 mAb and human PBMC from healthy donors. The isotype control
and PBMC alone were used as negative controls. Data from three independent experiments were analyzed by Students’s t-test and data are reported in the
ﬁgure as mean § SD.
Figure 3. BARF1 mAb in vivo biodistribution by ﬂuorescence analysis. Left panels show a representative SCID mouse injected s.c. on one ﬂank with C-666 NPC cells and on
the opposite one with MKN-45 GC cells (A), or with MKN-45 GC cells and BARF1-transduced MKN-45 GC cells (B), at two distinct sites. After i.v. injection of Alexa680-conju-
gated anti-BARF1 mAb, the ﬂuorescence was analyzed at different time points thereafter. Right panels show the histogram representation of ﬂuorescence intensity (p/
sec). The experiment was repeated twice with consistent results.
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cell s.c. model, the 3D4 mAb treatment strongly decreased pri-
mary tumor growth (p < 0.001; Fig. 4A), relative to the control.
Conversely, in mice injected s.c. with the EBVC BARF1-nega-
tive Raji cells, the treatment did not produce any therapeutic
effect (data not shown), consistent with in vitro results.
The C-666 cell line was also injected s.c. in RAG¡/¡
g-chain¡/¡ mice (which lack functional B, T and NK cells), but
no difference in cancer growth was observed between treated
and control group (p D 0.77; Fig. 4B), thus suggesting that the
main effector mechanism of the 3D4 mAb in vivo likely relies
on NK cells and ADCC.
To assess the systemic and metastatic behavior of the same
cell line upon i.v. injection, we took advantage of a biolumines-
cent model based on C-666 cells transduced with a luciferase
reporter gene. Under these experimental conditions, treatment
with the 3D4 mAb provided further strong evidence of thera-
peutic activity, as tumor growth was heavily delayed in treated
mice as compared with control animals and the metastatic pro-
gression almost completely abrogated (p D 0.02; Fig. 4C).
Moreover, mAb activity impacted on survival that signiﬁcantly
improved in treated vs. control mice (p D 0.03; Fig. 4D).
A similar approach was also adopted to assess the therapeu-
tic effects of 3D4 mAb in a different tumor model represented
by the s.c. or systemic injection of the GRANTA-519 cell line.
Upon s.c. inoculation, tumor growth was fast in the control
group, while appeared signiﬁcantly reduced in mAb-treated
mice (p < 0.001; Fig. 5A). As for the C-666 model, when per-
formed in RAG¡/¡ g-chain¡/¡ mice the same assay did not
bring about any signiﬁcant difference in GRANTA-519 tumor
growth (p D 0.14; Fig. 5B), thus underlying the importance of
ADCC as a functional mechanism of anti-BARF1 antibody.
When luciferase-transduced GRANTA-519 cells were adminis-
tered i.v., the treatment with the anti-BARF1 mAb again dra-
matically restrained tumor growth and dissemination (p D
0.03, Fig. 5C), and led to an improved survival (p D 0.002;
Fig. 5D).
Discussion
The dual tropism of the oncogenic EBV for B lymphocytes and
epithelial cells reﬂects on the development of both lymphomas
and carcinomas. Among them, only B-cell lymphomas can take
advantage of mAb therapy, being successfully treated by target-
ing some lineage-speciﬁc markers such as CD20, CD22, CD30,
CD37, CD52, and CD79a.26 However, these antibodies do not
discriminate between normal and malignant cells, thus leading
to the possible development of cytopenias and hypogammaglo-
bulinemia.26 In addition, a signiﬁcant percentage of patients
develops resistance.26 To overcome these limitations, we identi-
ﬁed the viral protein BARF1 as a speciﬁc and shared target for
a mAb therapy against potentially all EBV-related tumors, since
it is expressed as latency protein in EBV-driven carcinomas as
well as in lymphomas, at least as an early lytic protein in these
latter tumors. Further studies are, however, required to conclu-
sively assess the expression of BARF1 protein in EBV latently
infected lymphoma cells. Moreover, BARF1 was recently dem-
onstrated to be a good target for cell-based immunotherapeutic
strategies. Despite the fact that this protein is considered poorly
Figure 4. Therapeutic activity of BARF1 mAb in a NPC mouse model. On day 0, (A) SCID mice and (B) RAG¡/¡ g-chain¡/¡ mice were injected s.c. with 5£106 C-666
cells. Mab-treated mice (n D 9) received a total amount of 1 mg of the 3D4 anti-BARF1 antibody (white circles) starting at day 10 (palpable tumor), while control animals
(n D 5) were injected with PBS only (black squares). The therapy with the antibody signiﬁcantly delayed the tumor growth (p < 0.001) in A), while no effect was observ-
able in (B) (pD 0.77). (C) Bioluminescence analysis of SCID mice injected i.v. at day 0 with 3£106 C-666-LUX cells, and receiving anti-BARF1 mAb (1 mg) treatment accord-
ing to the previous schedule. Left panel refers to two representative treated and control mice 8 weeks after cell injection. Right graph shows cumulative BLI data from all
animals (control D 10 mice, treated D 12 mice) at different time points of analysis. Mab treatment signiﬁcantly reduced tumor growth (p D 0.02). (D) Kaplan-Meier sur-
vival curves of mice reported in (C): anti-BARF1 mAb therapy signiﬁcantly increased survival (p D 0.03).
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immunogenic, nevertheless both humoral and cellular immune
responses have been described in NPC patients.3,27 Of note,
EBV-speciﬁc CTL responses appeared to be protective to some
extent in a particular cohort of NPC patients, where the HLA
molecules that efﬁciently present CTL epitopes turned out to
be signiﬁcantly under-represented as compared with the gen-
eral population.28 Furthermore, BARF1-enriched EBV-speciﬁc
CTL cultures can be successfully generated through minimal
modiﬁcation of the protocol currently used in clinic.4
In the present work, we described the generation and func-
tional characterization of a new mouse mAb (3D4) that speciﬁ-
cally recognizes a BARF1 minimal epitope (aa 28–35) located
at the N-terminus of the molecule, in the region mediating
malignant cell transformation and Bcl¡2 upregulation.16 This
characteristic differentiates the 3D4 mAb from other reported
BARF1-speciﬁc antibodies, which preferentially target the C-
terminus of the molecule.27 More importantly, our results indi-
cate that the 3D4 mAb recognizes the target antigen in its
native conformation on the surface of tumor cell lines, as
assessed by ﬂow cytometry and functional tests. The detection
of BARF1 protein in tumor specimens by immunohistochemis-
try was, however, frustrated by negative results, probably due
to ﬁxation-dependent conformation loss, and/or shedding of
the molecule, as previously reported for other mAbs.12 Our
functional in vitro characterization showed that the 3D4 mAb
is able to speciﬁcally and effectively mediate both CDC and
ADCC activity against a panel of selected cell lines, whose
entity paralleled the intensity of BARF1 expression. In vivo
biodistribution analyses disclosed a speciﬁc and long-lasting
accumulation (up to 6 d) of the mAb on BARF1-expressing
tumors, a critical pre-requisite for the therapeutic activity of a
mAb. Moreover, our in vivo experiments demonstrated that
the 3D4 mAb is able to exert a signiﬁcant therapeutic activity
in both loco-regional and disseminated in vivo mouse models
of NPC and lymphoma. While NPC consistently express
BARF1 along with the LMP1 oncoprotein, the chosen model
for EBV-driven B-cell lymphoma (i.e., GRANTA-519 cell line)
is peculiar considering that it is still unclear whether BARF1
can be expressed by latently infected lymphoma cells in vivo.
Available data, however, support the rationale for the use of
BARF1 targeting antibodies for the treatment of EBVC lympho-
mas. In fact, BARF1-speciﬁc mAb therapy for lymphoma
patients could be associated and synergize with lytic cycle
inducers, such as doxorubicin.4 Albeit at different extents,
tumor-bearing mice treated with anti-BARF1 mAb underwent
a signiﬁcant inhibition of tumor mass growth and experienced
an improved survival, when compared with control groups.
Noteworthy, in the GRANTA-519 cell line model, i.v. injection
of anti-BARF1 antibody induced the complete regression of the
mass in 2/10 of treated mice. The lack of any therapeutic effect
shown in RAG¡/¡ g-chain¡/¡ mice strongly indicates that the
in vivo activity of the 3D4 mAb is mainly dependent on its abil-
ity to mediate ADCC, as also described for BARF1-speciﬁc
antibodies from NPC patient sera.21 In addition to these direct
effects on tumor cells, we could also expect an indirect antitu-
mor activity. Indeed, unlike BARF1-speciﬁc CTL therapy that
Figure 5. Therapeutic activity of BARF1 mAb in a lymphoma mouse model. On day 0, (A) SCID mice and (B) RAG¡/¡ g-chain¡/¡ mice were injected s.c. with 5£106
GRANTA-519 cells. Mab-treated mice (n D 13) received a total amount of 1 mg of the 3D4 anti-BARF1 antibody (white circles) starting at day 14 (palpable tumor), while
control animals (nD 9) were injected with PBS only (black squares). The therapy with the antibody signiﬁcantly delayed the tumor grow (p< 0.001) in (A), while no effect
was observable in B) (p D 0.14). (C) Bioluminescence analysis of SCID mice injected i.v. at day 0 with 3£106 GRANTA-519-LUX cells, and receiving anti-BARF1 mAb (1 mg)
treatment according to the previous schedule. Left panel refers to two representative treated and control mice 3 weeks after cell injection. Right graph shows cumulative
BLI data from all animals (10 mice/group) at different time points of analysis. Mab treatment signiﬁcantly reduced tumor growth (p D 0.03). (D) Kaplan-Meier survival
curves of mice reported in (C): anti-BARF1 mAb therapy signiﬁcantly increased survival (p D 0.002).
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can only targets antigens correctly presented at the cell surface
in a MHC-restricted context, BARF1-speciﬁc mAbs could also
recognize and block soluble molecules, thus potentially ham-
pering the mitogenic and immune-modulating activity of
BARF1 molecules shed in the tumor microenvironment. In
particular, since the mAb recognizes an epitope near the aa
involved in the interaction with hCSF-1 (aa 38–4118), it can be
expected to inﬂuence this link by sterical hindrance and poten-
tially relieve the inhibitory activity of BARF1 on monocytes.
This aspect is of particular interest in the case of NPC, where
the inﬁltration with mononuclear cells correlates with patient
survival.19 Unfortunately, in the mouse models used in the
present study, this potential additional beneﬁt cannot be appre-
ciated, because BARF1 does not interfere with the signaling
mediated by mouse CSF1R and CSF1 molecules.18 Despite this
limitation, these promising therapeutic results prompted us to
broaden the use of this new tool to other EBV-related malig-
nancies. Indeed, we obtained evidence that lymphoblastoid B
cells (LCL, the in vitro model of PTLD) are also positively
stained by our anti-BARF1 3D4 mAb (data not shown).
Taken together, these data further substantiate the role of
BARF1 as a novel EBV-speciﬁc antigen suitable for immuno-
therapeutic approaches, and provide evidence indicating that
the 3D4 anti-BARF1 mAb can be a potent tool for the detection
and treatment of several EBV-associated malignancies.
Materials and methods
Cell lines
The following human cell lines were used: GRANTA-519
(mantle B cell lymphoma, EBVC), C-666 (NPC, EBVC), BL-41
(Burkitt lymphoma, EBV¡), BL-41 B95.8 (the same cell line
infected with EBV), Raji (B lymphoblast-like cell, EBVC, but
BARF1¡), Bjab (Burkitt lymphoma, EBV¡), SNU-719 (GC,
EBVC) and MKN-45 (GC, EBV¡). All cell lines but SNU-719
and MKN-45 were cultured in RPMI-10 (RPMI 1640 medium,
Euroclone, with 10% heat-inactivated Foetal Bovine Serum,
FBS, Gibco, 10 mM HEPES Buffer, 1 mM Na Pyruvate, 2 mM
Ultraglutamine, all from Lonza BioWhittaker, and 1% Antibi-
otic/antimycotic, Gibco). SNU-719 and MKN-45 were cultured
in DMEM-10 (DMEM medium supplemented with the same
additives).
Antibody production
BARF1 sequence was analyzed using bioinformatic tools to
select potential exposed epitopes that could be accessible for
antibody binding. Three peptides derived from the main
potentially immunogenic epitopes were designed for
immunization, namely CVGKNDKEEAHGVYVSGYLSQ
(BARF1201–221), CRMKLGETEVTKQEHLS (BARF1104–120)
and RVTLTSYWRRV (BARF128–38), corresponding to aa
sequence of BARF1 protein 201–221, 104–120 and 28–38,
respectively. An additional residue of cysteine was added at
the N-terminal tail of peptide BARF128–38 to favor the conju-
gation to the carrier.
The peptides were synthesized at CRIBI (Padua University)
by solid-phase technique using a multiple peptides synthesizer
(SyroII, MultiSynTech GmbH) on a pre-loaded Wang resin
(100–200 mesh) (Novabiochem, Germany). The ﬂuoren-9-
ylmethoxycarbonyl (Fmoc) strategy was used throughout the
peptide chain assembly, using O-(7-azabenzotriazol-1-yl)-N,N,
N0,N0-tetramethyluronium hexaﬂuorophosphate (HATU) as
coupling reagent.
Peptides were conjugated to maleimide-activated KLH
(Keyhole Limpet Hemocyanin) by using Imject Maleimide
Activated mcKLH Kit (Thermo Scientiﬁc), and used for mice
immunizations. The anti-BARF1 hybridoma was derived by
fusing murine NS0 myeloma cells with the spleen cells from a
BALB/c mouse that had been immunized once subcutaneously
with 100 mg of each KLH-conjugated peptide in Complete
Freund Adjuvant (CFA, Sigma-Aldrich) and then twice with
100 mg of each KLH-conjugated peptide in Incomplete Freund
Adjuvant (IFA, Sigma-Aldrich). When necessary, additional
immunizations were performed in IFA. Splenocytes from the
immunized mouse were harvested and fused with NS0 mye-
loma cells using polyethyleneglycol (PEG, Sigma-Aldrich).
Hybridoma clones were screened for BARF1 reactivity by
enzyme-linked immunosorbent assay (ELISA) and ﬂow
cytometry. For ﬂow cytometry analysis, GRANTA-519 cells
were stained with the supernatant of the clones, and subse-
quently with a secondary FITC anti-mouse antibody (Dako);
ﬁnally, cells were analyzed using FACSCalibur (BD). Only
those clones that gave a positive stain as assessed by ﬂow
cytometry were used for the subsequent experiments. Anti-
body recognition was assessed by Dot Blot. Brieﬂy, we synthe-
sized two peptides with a 4-aminoacid overlap, derived from
the original 08/0828–39 peptide (used for all the experiments
described here). The peptides and the original 08/0828–39, 05/
08201–221 and 06/08104–120 peptides were blotted on a PVDF
membrane (Millipore) and stained with the anti-BARF1 mAb.
The positive signal was evaluated by chemioluminescence
using a ChemiDoc XRS instrument and QuantityOne (vers.
4.6) software (both from BioRad).
Flow cytometry analysis of BARF1 staining
BARF1-negative (BJAB, RAJI, BL-41) and -positive (GRANTA-
519, C-666, BL-41 B95.8 and SNU-719) cell lines were stained
with the anti-BARF1 mAb. Moreover, we generated a BARF1-
transduced cell line by transducing MKN-45 cells with a
BARF-1 retrovirus.4
Evaluation of complement-dependent cytotoxicity (CDC)
Target cells (6£105 GRANTA-519, C-666, BL-41, BL-41 B95.8
cells and SNU-719) were labeled with 100 mCi Na2
51CrO4
(PerkinElmer). After addition of 1 mg anti-BARF1 mAb, cells
were incubated in 200 mL RPMI-25% Human Serum (non-
heat inactivated; Lonza), for 1 h at 37C. Negative controls
(or spontaneous release) were cells without mAb, while for
positive control (maximum release) 100 mL Triton 5%
(Sigma-Aldrich) were added. Supernatant radioactivity was
evaluated by using a g-ray counter (Cobra Gamma Counting
System, Packard Instrument Company). The percentage of
speciﬁc cell lysis was calculated as follows: 100 £ [(A ¡ C)/
(B ¡ C)], where A represents an absorbance obtained with
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test serum (experimental release), C and B the minimum
(heat-inactivated serum) and maximum release (with Triton
5%), respectively.
Evaluation of antibody-dependent cell-mediated
cytotoxicity (ADCC)
ADCC was performed following Calcein-AM (Invitrogen) pro-
tocol. Brieﬂy, 1£106 target cells were re-suspended in 1 mL
Hank’s Balanced Salt Solution added with 5% FBS (HBSS-FBS)
and labeled with 7.5 mL of Calcein-AM 1 mg/mL for 30 min at
37 C. Cells were then labeled with anti-BARF1 mAb at a con-
centration of 20 mg/mL, 10 mg/mL and 5 mg/mL, while nega-
tive controls were performed with HBSS-FBS only. As a
positive control, target cells were lysed with Triton 5%. Cells
were seeded, and effector cells were added: freshly thawed
PBMC from healthy donors were seeded at different effector-
target ratios (300:1, 150:1 and 75:1) for 4 h at 37C, then
100 mL of supernatant were collected and seeded on a 96-well
Black OptiPlate (Nunc). After 15 min at RT, the plate was read
at 485 nm using Victor X3 Multilabel Plate reader. Lysis per-
centage (% Lys) was calculated as in CDC.
Mice
In vivo experiments involved 6- to 8-week-old SCID, RAG¡/¡
g-chain¡/¡ and BALB/c mice (Charles River Laboratories),
which were housed in our Speciﬁc Pathogen Free (SPF) animal
facility. Procedures involving animals and their care were con-
ducted according to institutional guidelines that comply with
national and international laws and policies (D.L. 116/92 and
subsequent implementing circulars), and the experimental pro-
tocol (project ID: 2/2012) was approved by the local Ethical
Committee of Padua University (CEASA). During in vivo
experiments, animals in all experimental groups were examined
daily for a decrease in physical activity and other signs of dis-
ease; severely ill animals (weight loss exceeding 15%, lethargy,
rufﬂed hair, low temperature) were killed by carbon dioxide
overdose.
Biodistribution analysis
To study the antibody biodistribution, anti-BARF1 mAb was
conjugated to Alexa 680 using SAIVI Rapid Antibody Labeling
Kit (Invitrogen), and following the manufacturer’s indications.
SCID mice were injected s.c. on one ﬂank with an EBV-nega-
tive cell line (MKN-45) and on the opposite one with a BARF1-
positive cell line (C-666 or BARF1-transduced MKN-45). As
soon as both tumors became palpable, 100 mg Alexa-680 anti-
BARF1 antibody were injected via tail vein in the anaesthetized
animal, and the ﬂuorescence signal was analyzed by total body
scanning every 24 h using an MX2 apparatus (ART, Canada),
as previously reported.25, 29
Assessment of therapeutic efﬁcacy
Six-to-eight-week-old SCID and RAG¡/¡ g-chain¡/¡ mice
were injected s.c. with 5£106 C-666 or GRANTA-519 cells.
Mice were then divided into untreated and treated groups,
which received PBS or 1 mg anti-BARF1 mAb (5 i.p. injections
of 0.2 mL each, one every 2 d), respectively, starting from day
10 or 14 after C-666 or GRANTA-519 tumor injection, respec-
tively. Tumor masses were evaluated every 2 d by measuring
maximum and minimum diameter, and tumor volume was cal-
culated applying the formula: (d£d£D)/2, where d and D are
the minimum and maximum diameters, respectively. More-
over, tumor cell lines were transduced with a ﬁreﬂy luciferase-
encoding lentiviral (LV-LUX) vector as described previously.30
In different experiments, SCID mice were injected i.v. with
3£106 Luciferase-transduced C-666 or GRANTA-519 cells.
Then, treated mice received from day 10 (C-666) or 14
(GRANTA-519) and weekly thereafter 0.3 mg/mouse of anti-
BARF1 mAb. Bioluminescence (BLI) images were acquired at
different time points after in vivo cell injection using the IVIS
Lumina II Imaging System (PerkinElmer). Ten minutes before
each imaging session, animals were anaesthetized with isoﬂur-
ane/oxygen and administered i.p. with 150 mg/kg of D-luciferin
(PerkinElmer) in Dulbecco’s Phosphate-Buffered Saline
(DPBS), and the signal intensity was measured as radiance
(photon/sec) using the LivingImage software 3.2 (Perki-
nElmer). Tumor growth and response to therapy were moni-
tored by BLI and by recording survival.
Statistical analysis
Both for the tumor growth and the BLI analysis, ANOVA for
repeated measures test was performed between control and
treated group, using MedCalc, version 9.4.2.0. Survival dia-
grams and analysis of the survival data (using Kaplan-Meier
test) were performed with the same statistical software.
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